DarioHealth Corp. (DRIO)
| Market Cap | 27.54M -12.0% |
| Revenue (ttm) | 21.00M -22.7% |
| Net Income | -7.00M |
| EPS | -0.95 |
| Shares Out | 9.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,653 |
| Open | 2.950 |
| Previous Close | 2.970 |
| Day's Range | 2.690 - 2.950 |
| 52-Week Range | 2.690 - 14.770 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 12.33 (+338.79%) |
| Earnings Date | Nov 12, 2026 |
About DRIO
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the sympt... [Read more]
Financial Performance
In 2025, DarioHealth's revenue was $22.36 million, a decrease of -17.31% compared to the previous year's $27.04 million. Losses were -$40.31 million, 34.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for DRIO stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 338.79% from the latest price.
News
Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care
Mr. Palumbo to join Dario's third quarter 2026 earnings call to share the Board's view on the convergence of consumer and payer-led healthcare and chronic care management NEW YORK, Nov. 4, 2026 /PRNew...
DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading artificial intellige...
DarioHealth initiated with a Buy at BTIG
BTIG analyst David Larsen initiated coverage of DarioHealth (DRIO) with a Buy rating and $6 price target The firm says DarioHealth is a multi-condition, vertically integrated digital health platform w...
DarioHealth extends contract with regional grocery retailer for women’s health
DarioHealth (DRIO) announced that a regional grocery retailer client has expanded its contract with Dario to add Dario Women, the company’s recently launched women’s health solution supporting women n...
Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support Nearly 45% of Dario's current book of business is women over age ...
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 stu...
DarioHealth announces new contract with health plan in New Jersey
DarioHealth (DRIO) announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5M covered lives. The agreement was secured…
Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives
Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy Program for Dario's cardiometabolic suite and provider-backed care expect...
DarioHealth initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of DarioHealth (DRIO) with a Buy rating and $12 price target DarioHealth is a vertically integrated health intelligence platform that is utilized...
DarioHealth price target lowered to $8 from $11 at TD Cowen
TD Cowen lowered the firm’s price target on DarioHealth (DRIO) to $8 from $11 and keeps a Hold rating on the shares. The firm updated its model following softer Q2…
DarioHealth trading halted, volatility trading pause
09:57 EDT DarioHealth (DRIO) trading halted, volatility trading pause
DarioHealth Earnings Call Transcript: Q2 2026
Q2 2026 saw improved gross margin and reduced net loss amid a strategic shift to recurring B2B2C revenue. Over $13M in contracted ARR, mostly multi-condition, is set to convert over the next 4-5 quarters, with AI and new care offerings expected to drive future growth.
DarioHealth Quarterly report: Q2 2026
DarioHealth has published its Q2 2026 quarterly earnings report on August 11, 2026.
DarioHealth Earnings release: Q2 2026
DarioHealth released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
DarioHealth Reports Second Quarter 2026 Financial Results
Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the f...
Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider...
DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intellige...
DarioHealth launches integrated GLP-1 Program
DarioHealth (DRIO) announced the launch of Dario’s Integrated GLP-1 Program, the first commercial offering built on the company’s recently announced collaboration with Beluga Health. Dario has support...
Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Comm...
DarioHealth prices 3.45M shares at $6.80 in registered direct offering
DarioHealth (DRIO) announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale...
Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor NEW YORK, July 22, 2026 /PRNewswi...
DarioHealth trading halted, volatility trading pause
09:41 EDT DarioHealth (DRIO) trading halted, volatility trading pause
DarioHealth selected to deliver AI-powered cardiometabolic care platform
DarioHealth (DRIO) announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The ...